Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): Long-term follow-up results of RTOG 0132.
D. Wang
No relevant relationships to disclose
Q. Zhang
No relevant relationships to disclose
C. D. Blanke
Consultant or Advisory Role - Novartis
Honoraria - Novartis
G. D. Demetri
Employment or Leadership Position - Kolltan Pharmaceuticals (U); N-of-One (U); Plexxikon (U); ZIOPHARM Oncology (U)
Consultant or Advisory Role - Alnylam; Amgen; ARIAD; ArQule; Bayer; Champions Biotechnology; Daiichi Sankyo; EMD Serono; Enzon; Genentech; GlaxoSmithKline; Idera Pharmaceuticals; Infinity; Johnson & Johnson; Kolltan Pharmaceuticals (U); Millennium; N-of-One (U); Novartis; Pfizer; Plexxikon; ZIOPHARM Oncology
Stock Ownership - Champions Biotechnology; Kolltan Pharmaceuticals; N-of-One ; Plexxikon
Honoraria - Novartis; Pfizer
Research Funding - ARIAD; Bristol-Myers Squibb; Daiichi Sankyo; Infinity; Johnson & Johnson; Novartis; Pfizer
Expert Testimony - Bayer (U); Infinity (U); Merck (U); Novartis (U); Pfizer (U)
M. C. Heinrich
Consultant or Advisory Role - MolecularMD
Stock Ownership - MolecularMD
Research Funding - Arog; ImClone Systems; Novartis
J. C. Watson
Honoraria - Novartis
J. P. Hoffman
No relevant relationships to disclose
S. H. Okuno
No relevant relationships to disclose
J. M. Kane
No relevant relationships to disclose
M. vonMehren
No relevant relationships to disclose
B. L. Eisenberg
Employment or Leadership Position - Novartis (U)
Consultant or Advisory Role - Novartis
Honoraria - Novartis